March 29, 2021 -- Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for NeuMoDx, a test that helps clinicians distinguish types of respiratory disease.
NeuMoDx Flu A-B/ respiratory syncytial virus (RSV)/SARS-CoV-2 Vantage is a polymerase chain reaction (PCR) assay that will enable clinicians to identify the cause of respiratory viral infection, whether it's due to SARS-CoV-2, influenza, or RSV.
The test has been in use in the European Union since last November, Qiagen said.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current